References
1. Bartelink IH, Lalmohamed A, van Reij EML, et al. Association of busulfan exposure with survival and toxicity after haemopoietic cell transplantation in children and young adults: a multicentre, retrospective cohort analysis. Lancet Haematol . 2016;3(11):e526-e536. doi:10.1016/S2352-3026(16)30114-4
2. Dix SP, Wingard JR, Mullins RE, et al. Association of busulfan area under the curve with veno-occlusive disease following BMT. Bone Marrow Transplant . 1996;17(2):225-230. http://www.ncbi.nlm.nih.gov/pubmed/8640171.
3. Malär R, Sjöö F, Rentsch K, Hassan M, Güngör T. Therapeutic drug monitoring is essential for intravenous busulfan therapy in pediatric hematopoietic stem cell recipients. Pediatr Transplant . 2011;15(6):580-588. doi:10.1111/j.1399-3046.2011.01529.x
4. Güngör T, Teira P, Slatter M, et al. Reduced-intensity conditioning and HLA-matched haemopoietic stem-cell transplantation in patients with chronic granulomatous disease: a prospective multicentre study.Lancet . 2014;383(9915):436-448. doi:10.1016/S0140-6736(13)62069-3
5. Horn B, Baxter-Lowe L-A, Englert L, et al. Reduced intensity conditioning using intravenous busulfan, fludarabine and rabbit ATG for children with nonmalignant disorders and CML. Bone Marrow Transplant . 2006;37(3):263-269. doi:10.1038/sj.bmt.1705240
6. McCune JS, Bemer MJ, Barrett JS, Scott Baker K, Gamis AS, Holford NHG. Busulfan in Infant to Adult Hematopoietic Cell Transplant Recipients: A Population Pharmacokinetic Model for Initial and Bayesian Dose Personalization. Clin Cancer Res . 2014;20(3):754-763. doi:10.1158/1078-0432.CCR-13-1960
7. Nguyen L, Fuller D, Lennon S, Leger F, Puozzo C. I.V. busulfan in pediatrics: a novel dosing to improve safety/efficacy for hematopoietic progenitor cell transplantation recipients. Bone Marrow Transplant . 2004;33(10):979-987. doi:10.1038/sj.bmt.1704446
8. Matsumoto K, Uchida N, Sakurai A, Taniguchi S, Morita K. Clinical Application of the Dried Blood Spot Method in the Measurement of Blood Busulfan Concentration. Biol Blood Marrow Transplant . 2016;22(11):1968-1973. doi:10.1016/j.bbmt.2016.07.008
9. Watanabe E, Nishikawa T, Ikawa K, et al. Trough level monitoring of intravenous busulfan to estimate the area under the plasma drug concentration–time curve in pediatric hematopoietic stem cell transplant recipients. Int J Hematol . 2015;102(5):611-616. doi:10.1007/s12185-015-1853-6
10. Kishimoto K, Hasegawa D, Irie K, et al. Pharmacokinetic analysis for model‐supported therapeutic drug monitoring of busulfan in Japanese pediatric hematopoietic stem cell transplantation recipients.Pediatr Transplant . 2020;24(4):1-7. doi:10.1111/petr.13696
11. Evaluation and Licensing Division; Pharmaceutical and Food Safety Bureau; Ministry of Health; Labour and Welfare. Guideline on Bioanalytical Method Validation in Pharmaceutical Development. https://www.pmda.go.jp/files/000206209.pdf. Accessed December 30, 2020.
12. Kangarloo SB, Naveed F, Ng ESM, et al. Development and Validation of a Test Dose Strategy for Once-Daily i.v. Busulfan: Importance of Fixed Infusion Rate Dosing. Biol Blood Marrow Transplant . 2012;18(2):295-301. doi:10.1016/j.bbmt.2011.07.015
13. Tsujimoto S, Shirai R, Utano T, et al. Comparison of clonazepam and levetiracetam in children for prevention of busulfan-induced seizure in hematopoietic stem cell transplantation. Int J Hematol . 2020;111(3):463-466. doi:10.1007/s12185-019-02795-8
14. Carreras E, Cahn JY, Puozzo C, Kröger N, Sanz G, Buzyn A. Influence on Busilvex ® Pharmacokinetics of Clonazepam Compared to Previous Phenytoin Historical Data. Anticancer Res . 2010;2984(30):2977-2984.
15. Nishikawa T, Yamaguchi H, Ikawa K, et al. Influence of <scp>GST</scp> polymorphisms on busulfan pharmacokinetics in Japanese children.Pediatr Int . 2019;61(6):ped.13859. doi:10.1111/ped.13859
16. Gibbs JP, Liacouras CA, Baldassano RN SJ. Up-regulation of glutathione S-transferase activity in enterocytes of young children.Drug Metab Dispos . 1999;27(12):1466-1469.